QUANTA


Associated tags: RAS, Research, Therapy, Drug development, SHG, Generator, Prostate, OncoMed, Faculdade de Medicina da Universidade Federal de Minas Gerais, Business administration, Mutation, University of California, Berkeley, Senior, University, Clinical professor, Patient, KRAS, Pharmaceutical industry, Cabozantinib, Quanta, Lung, Internal medicine

Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, December 13, 2022
Prostate, Master's degree, Universiade, Protein, Drug discovery, Neoplasm, Breast, SAN, Mayo Clinic, FDA, RAS, Cancer, General of the branch, Chicago (franchise), Columbia University, Doctor of Philosophy, Bevacizumab, Genentech, MD, Internal medicine, Drug development, Lung, SHG, Growth, Faculdade de Medicina da Universidade Federal de Minas Gerais, Business administration, Research, Mutation, Therapy, University of California, Berkeley, OncoMed, Senior, University, Clinical professor, Patient, KRAS, Pharmaceutical industry, Cabozantinib, Quanta, Exelixis

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer. Dr. Faoro brings more than 13 years of global clinical and regulatory experience advancing oncology medicines from early development stages through to approval, most recently serving as Senior Vice President and Early Clinical Development Lead at Exelixis, where he provided strategic leadership to expand the company's early clinical oncology pipeline and advance development candidates into the clinic.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer.
  • “We have made tremendous progress in advancing our novel RAS-targeted discovery programs with a unique focus on disrupting the active RAS signaling complex,” said Perry Nisen, MD, PhD, Chief Executive Officer of Quanta Therapeutics.
  • Quanta Therapeutics aims to advance two differentiated, next-generation RAS programs that address the resistance paradigms of targeted therapy in oncology.
  • Quanta Therapeutics is a private biopharmaceutical company focused on the most prevalent and elusive target in oncology—RAS.

Quanta System SpA on the Way to Introduce Its New ''UHPTDL'' Lithotripsy Technology in H2 2020

Retrieved on: 
Friday, January 10, 2020
Technology, Medical devices, Surgery, Other Technology, Other Health, Biotechnology, Hardware, Health, Science, Other Science, Physical sciences, Chemistry, Laser medicine, Laser lithotripsy, Natural sciences, Lithotripsy, Thulium, Laser, Quanta

The worldwide laser lithotripsy market has been very strong over the last 10 years, notes Paolo Salvadeo, General Manager of El.En.

Key Points: 
  • The worldwide laser lithotripsy market has been very strong over the last 10 years, notes Paolo Salvadeo, General Manager of El.En.
  • Filippo Fagnani, Quanta System Surgical Division Scientific Director adds: A new technology based on Thulium doped fibers has been introduced in the lithotripsy field.
  • Once technology is fully engineered, the new laser system will seek regulatory clearance worldwide, including the United Stated of America.
  • Quanta System is the reference partner for healthcare facilities, institutions and authorities involved in scientific and research projects worldwide.

Cook Medical and Quanta System Announce Distribution Agreement for Laser Systems

Retrieved on: 
Wednesday, October 30, 2019
Surgery, Medical devices, Medical Supplies, Hospitals, Biotechnology, Other Health, Radiology, Health, General Health, Physical sciences, Chemistry, Chemical substances, Chemical elements, Lanthanides, Reducing agents, Quantum optics, Laser, Photonics, Quanta, Thulium, Holmium(III) oxide, Surgery, Medical devices, Medical Supplies, Hospitals, Biotechnology, Other Health, Radiology, Health, General Health, Physical sciences, Chemistry, Chemical substances, Chemical elements, Lanthanides, Reducing agents, Quantum optics, Laser, Photonics, Quanta, Thulium, Holmium(III) oxide, Cook Medical, Quanta

Cook Medical and Quanta System have entered into an agreement in which Cook will distribute a comprehensive offering of Quantas holmium and thulium laser systems, laser fibers and accessories.

Key Points: 
  • Cook Medical and Quanta System have entered into an agreement in which Cook will distribute a comprehensive offering of Quantas holmium and thulium laser systems, laser fibers and accessories.
  • Quanta is a progressive laser manufacturer with an expanding global presence, and we are eager to bring Quantas robust line of laser systems and fibers to Cooks customers.
  • The Quanta laser systems will be available in the United States beginning in late 2019 and in other countries in 2020.
  • Quanta System is a 100% Italian company that has offered on the global market innovative laser systems for surgery, aesthetics and art conservation since 1985.